High cholesterol secondary prevention: Difference between revisions
Kashish Goel (talk | contribs) No edit summary |
Kashish Goel (talk | contribs) No edit summary |
||
| Line 9: | Line 9: | ||
==Therapy goals== | ==Therapy goals== | ||
NCEP ATP III guidelines recommended a LDL goal < 100 mg/dL for CHD or CHD risk equivalents, however drug therapy was considered optional between a LDL of 100 to <130 mg/dL. An update by the NCEP committee in 2004 based on new trial data recommended starting drug therapy simultaneously with therapeutic lifestyle changes in CHD patients with LDL < 100 mg/dL. | |||
==Evidence incorporated in NCEP guidelines== | ==Evidence incorporated in NCEP guidelines== | ||
Revision as of 15:16, 12 September 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Associate Editor(s)-In-Chief: Kashish Goel, M.D.
Overview
Patients with [coronary heart disease] or newly diagnosed [acute coronary syndrome] are at a high risk of recurrent coronary events. In addition to modification of lifestyle factors, LDL lowering has been shown to reduce recurrent events, cardiovascular deaths and all-cause mortality in these patients. According to the [NCEP ATP III guidelines], LDL cholesterol of < 100 mg/dL is the goal in patients with CHD and CHD risk equivalents. However, some of the recent trial evidence suggested a more aggressive approach with a target LDL < 70 mg/dL. The NCEP recommendations are mentioned here, in addition to recent evidence.
Therapy goals
NCEP ATP III guidelines recommended a LDL goal < 100 mg/dL for CHD or CHD risk equivalents, however drug therapy was considered optional between a LDL of 100 to <130 mg/dL. An update by the NCEP committee in 2004 based on new trial data recommended starting drug therapy simultaneously with therapeutic lifestyle changes in CHD patients with LDL < 100 mg/dL.